Hepion Pharmaceuticals (HEPA)
(Real Time Quote from BATS)
$1.38 USD
-0.08 (-5.57%)
Updated Apr 23, 2024 12:28 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Income Statements
Fiscal Year end for Hepion Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 48 | 45 | 30 | 20 | 8 |
Income After Depreciation & Amortization | -48 | -45 | -30 | -20 | -8 |
Non-Operating Income | -1 | 0 | -2 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 1 |
Pretax Income | -49 | -45 | -33 | -20 | -8 |
Income Taxes | 0 | -3 | 0 | 0 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -49 | -42 | -33 | -20 | -7 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -49 | -42 | -33 | -20 | -7 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -45 | -44 | -30 | -20 | -7 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | 0 | 0 | 1 |
Income After Depreciation & Amortization | -48 | -45 | -30 | -20 | -8 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.97 | NA | 3.52 | 0.48 | 0.10 |
Diluted EPS Before Non-Recurring Items | -12.32 | NA | -9.40 | -42.00 | -119.00 |
Diluted Net EPS (GAAP) | -12.32 | -11.80 | -9.40 | -42.00 | -119.00 |
Fiscal Year end for Hepion Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 10.41 | 10.67 | 14.16 | 13.21 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -10.41 | -10.67 | -14.16 | -13.21 |
Non-Operating Income | NA | -1.06 | 0.14 | 0.09 | -0.05 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -11.47 | -10.53 | -14.08 | -13.26 |
Income Taxes | NA | -0.41 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -11.06 | -10.53 | -14.08 | -13.26 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -11.06 | -10.53 | -14.08 | -13.26 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 3.97 | 3.84 | 3.83 | 3.81 |
Diluted EPS Before Non-Recurring Items | NA | -2.42 | -2.74 | -3.68 | -3.48 |
Diluted Net EPS (GAAP) | NA | -2.42 | -2.74 | -3.68 | -3.48 |